Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gilles Berger

Showing results (1-10 of 43) with videos related to

Pageof 5
Sort By:
Pharmaceutical Patent Analyst|October 16, 2019
Pharmaceutical patent landscape for cancer immunotherapy: an interview with Gilles BergerGilles Berger
Future Medicinal Chemistry|December 12, 2018
Novel non-nucleotidic STING agonists for cancer immunotherapyGilles Berger, Sean E Lawler
Chemical Communications (Cambridge, England)|April 17, 2020
Halogen bonding for molecular recognition: new developments in materials and biological sciencesGilles Berger, Pierre Frangville, Franck Meyer
The Journal of Organic Chemistry|March 6, 2020
Design and Synthesis of Backbone-Fused, Conformationally Constrained Morpholine-Proline ChimerasSofiane Hocine, Gilles Berger, Stephen Hanessian
Trends in Molecular Medicine|March 20, 2019
Pharmacological Modulation of the STING Pathway for Cancer ImmunotherapyGilles Berger, Mickaël Marloye, Sean E Lawler
Angewandte Chemie (International Ed. in English)|September 9, 2015
Structural Properties and Stereochemically Distinct Folding Preferences of 4,5-cis and trans-Methano-L-Proline Oligomers: The Shortest Crystalline PPII-Type Helical Proline-Derived TetramerGilles Berger, Miguel Vilchis-Reyes, Stephen Hanessian
Pharmaceutical Patent Analyst|July 30, 2019
Current patent and clinical status of stimulator of interferon genes (STING) agonists for cancer immunotherapyMickaël Marloye, Sean E Lawler, Gilles Berger
The Journal of Organic Chemistry|June 3, 2016
Strategies toward the Total Synthesis of Calyciphylline B-type Alkaloids: A Computational Perspective Aided by DFT AnalysisAmit Kumar Chattopadhyay, Gilles Berger, Stephen Hanessian
Future Medicinal Chemistry|November 23, 2016
A survey of the mechanisms of action of anticancer transition metal complexesMickaël Marloye, Gilles Berger, Michel Gelbcke, et al.
Inorganic Chemistry|April 19, 2021
Reduction Mechanisms of Anticancer Osmium(VI) Complexes Revealed by Atomic Telemetry and Theoretical CalculationsGilles Berger, Anna Wach, Jacinto Sá, et al.
Pageof 5

Showing results (1-10 of 43) with videos related to

Sort By:
Pageof 5
Pharmaceutical Patent Analyst|October 16, 2019
Pharmaceutical patent landscape for cancer immunotherapy: an interview with Gilles BergerGilles Berger
Future Medicinal Chemistry|December 12, 2018
Novel non-nucleotidic STING agonists for cancer immunotherapyGilles Berger, Sean E Lawler
Chemical Communications (Cambridge, England)|April 17, 2020
Halogen bonding for molecular recognition: new developments in materials and biological sciencesGilles Berger, Pierre Frangville, Franck Meyer
The Journal of Organic Chemistry|March 6, 2020
Design and Synthesis of Backbone-Fused, Conformationally Constrained Morpholine-Proline ChimerasSofiane Hocine, Gilles Berger, Stephen Hanessian
Trends in Molecular Medicine|March 20, 2019
Pharmacological Modulation of the STING Pathway for Cancer ImmunotherapyGilles Berger, Mickaël Marloye, Sean E Lawler
Angewandte Chemie (International Ed. in English)|September 9, 2015
Structural Properties and Stereochemically Distinct Folding Preferences of 4,5-cis and trans-Methano-L-Proline Oligomers: The Shortest Crystalline PPII-Type Helical Proline-Derived TetramerGilles Berger, Miguel Vilchis-Reyes, Stephen Hanessian
Pharmaceutical Patent Analyst|July 30, 2019
Current patent and clinical status of stimulator of interferon genes (STING) agonists for cancer immunotherapyMickaël Marloye, Sean E Lawler, Gilles Berger
The Journal of Organic Chemistry|June 3, 2016
Strategies toward the Total Synthesis of Calyciphylline B-type Alkaloids: A Computational Perspective Aided by DFT AnalysisAmit Kumar Chattopadhyay, Gilles Berger, Stephen Hanessian
Future Medicinal Chemistry|November 23, 2016
A survey of the mechanisms of action of anticancer transition metal complexesMickaël Marloye, Gilles Berger, Michel Gelbcke, et al.
Inorganic Chemistry|April 19, 2021
Reduction Mechanisms of Anticancer Osmium(VI) Complexes Revealed by Atomic Telemetry and Theoretical CalculationsGilles Berger, Anna Wach, Jacinto Sá, et al.
Pageof 5